Visual signs and symptoms of progressive supranuclear palsy

REFERENCES

• Steele JC, Richardson JC, Olszewski T. Progressive supranuclear palsy. Arch Neurol 1964; 10: 333–359.
   PubMed Web of Science ®Google Scholar
• Armstrong RA. Visual signs and symptoms of Parkinson's disease. Clin Exp Optom 2008; 91: 129–138.
   PubMed Web of Science ®Google Scholar
• Armstrong RA, Cairns NJ, Lantos PL. A quantitative study of the pathological changes in ten patients with multiple system atrophy (MSA). J Neural Transm 2004; 111: 485–495.
   Web of Science ®Google Scholar
• Armstrong RA, Cairns NJ. Clustering and spatial correlations of the neuronal cytoplasmic inclusions, astrocytic plaques and ballooned neurons in corticobasal degeneration. J Neural Transm 2009; 116: 1103–1110.
   Web of Science ®Google Scholar
• Armstrong RA, Cairns NJ, Lantos PL. The spatial patterns of Lewy bodies, senile plaques and neurofibrillary tangles in dementia with Lewy bodies. Exp Neurol 1998; 150: 122–127.
   Web of Science ®Google Scholar
• Nath U, Ben‐shlomo Y, Thomson RG, Morris HR, Wood NW, Lees AJ, Burn DJ. The prevalence of progressive supranuclear palsy (Steele‐Richardson‐Olszewski syndrome) in the UK. Brain 2001; 124: 1438–1449.
   PubMed Web of Science ®Google Scholar
• Golbe LI, Davis PH, Schoenberg BS, Duvoisin RC. Prevalence and natural history of progressive supranuclear palsy. Neurology 1988; 38: 1031–1034.
   PubMed Web of Science ®Google Scholar
• Schrag A, Ben‐shlomo Y, Quinn NP. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross‐sectional study. Lancet 1999; 354: 1771–1775.
   PubMed Web of Science ®Google Scholar
• Bower JH, Maraganore DM, Mcdonnell K, Rocca WA. Incidence of progressive supranuclear palsy and multiple system atrophy in Olmstead County, Minnesota, 1976–1990. Neurology 1997; 49: 1284–1288.
   PubMed Web of Science ®Google Scholar
• Rojo A, Pernaute RS, Fontan A, Ruiz PG, Honnorat J, Lynch T, Chin S et al. Clinical genetics of familial progressive supranuclear palsy. Brain 1999; 122: 1233–1245.
   Web of Science ®Google Scholar
• Dickson DW. Neuropathological differentiation of progressive supranuclear palsy and corticobasal degeneration. J Neurol 1999; 246: 6–15.
   Web of Science ®Google Scholar
• Stanford PM, Halliday GM, Brooks WS, Kwok JBJ, Storey CE, Creasey H, Morris JGL et al. Progressive supranuclear palsy pathology caused by a novel silent mutation in exon 10 of the tau gene: expansion of the disease phenotype caused by the tau gene mutations. Brain 2000; 123: 880–893.
   PubMed Web of Science ®Google Scholar
• Higgins JJ, Adler RL, Loveless JM. Mutational analysis of the tau gene in progressive supranuclear palsy. Neurology 1999; 53: 1421–1424.
   Web of Science ®Google Scholar
• Hoenicka J, Perez M, Perez‐tur J, Barabash A, Godoy M, Vidal L, Astarloa A et al. The tau gene AO allele and progressive supranuclear palsy. Neurology 1999; 53: 1219–1225.
   Web of Science ®Google Scholar
• Swerdlow RH, Golbe LI, Parks JK, Cassarino DS, Binder DR, Grawey AE, Litvan I et al. Mitochondrial dysfunction in cybrid lines expressing mitochondrial genes from patients with progressive supranuclear palsy. J Neurochem 2000; 75: 1681–1684.
   PubMed Web of Science ®Google Scholar
• Posey WC. Paralysis of the upward movement of the eyes. Ann Ophthalmol 1904; 13: 523–531.
   Google Scholar
• Spiller WG. The importance in clinical diagnosis of paralysis of associated movements of the eyeballs (Blick‐Lahmung), especially of upward and downward associated movements. J Nerv Ment Dis 1905; 32: 417–448.
   Google Scholar
• Papapetropoulos S, Gonzalez J, Mash DC. Natural history of progressive supranuclear palsy: a clinicopathologic study from a population of brain donors. Eur Neurol 2005; 54: 1–9.
   Web of Science ®Google Scholar
• Armstrong RA. Parkinson's disease and the eye. Ophthalmic Physiol Opt 1997; 17: S9‐S16.
   Web of Science ®Google Scholar
• Gomez‐haro C, Espert‐tortajada R, Gadea‐domenech M, Navarro‐humanes JF. Progressive supranuclear palsy: Neurological, neuropathological and neuropsychological aspects. Rev de Neurol 1999; 29: 936–956.
   Web of Science ®Google Scholar
• Armstrong RA, Lantos PL, Cairns NJ. Progressive supranuclear palsy (PSP): a quantitative study of the pathological changes in cortical and subcortical areas of eight cases. J Neural Transm 2007; 114: 1569–1577.
   Web of Science ®Google Scholar
• Williams DR, De silva R, Paviour DC, Pittman A, Watt HC, Kilford L, Holton JL et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP‐parkinsonism. Brain 2005; 128: 1247–1258.
   PubMed Web of Science ®Google Scholar
• Lantos PL. The neuropathology of progressive supranuclear palsy. J Neural Transm 1994; 42: 137–152.
   Google Scholar
• Armstrong RA. Is the clustering of neurofibrillary tangles in Alzheimer's patients related to the cells of origin of specific cortico‐cortical projections? Neurosci Lett 1993; 160: 57–60.
   Web of Science ®Google Scholar
• Conrad C, Andreadis A, Trojanwski JQ, Dickson DW, Kang D, Chen XH, Wiederholt W et al. Genetic evidence for the involvement of tau in progressive supranuclear palsy. Ann Neurol 1997; 41: 277–281.
   PubMed Web of Science ®Google Scholar
• Yamada T, Mcgeer PL, Mcgeer EG. Appearance of paired nucleated tau‐positive glia in patients with progressive supranuclear palsy brain tissue. Neurosci Lett 1992; 135: 99–102.
   PubMed Web of Science ®Google Scholar
• Ikeda K, Akiyama H, Kondo H, Haga C, Tanno E, Tokuda T, Ikeda S. Thorn‐shaped astrocytes: possibly secondarily induced tau‐positive glial fibrillary tangles. Acta Neuropathol 1995; 90: 620–625.
   PubMed Web of Science ®Google Scholar
• Komori T. Tau positive glial inclusions in progressive supranuclear palsy, corticobasal degeneration and Pick's disease. Brain Pathol 1999; 9: 663–679.
   PubMed Web of Science ®Google Scholar
• Burns DJ, Lee AJ. Progressive supranuclear palsy: where are we now? Lancet Neurol 2002; 1: 359–369.
   Web of Science ®Google Scholar
• Punal‐rioboo J, Serena‐puig A, Varela‐lema L, Alvarez‐paez M, Ruana‐ravina A. Clinical utility of F‐18‐DOPA‐PET in movement disorders. A systematic review. Rev Exp de Med Nuc 2009; 28: 106–113.
   Web of Science ®Google Scholar
• Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Davoisin RC, Goetz CG et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele‐Richardson‐Olszewski syndrome): report of the NINDS‐SPSP International Workshop. Neurology 1996; 47: 1–9.
   PubMed Web of Science ®Google Scholar
• Hauw JJ, Daniel SE, Dickson D, Horoupian DS, Jellinger K, Lantos PL, Mckee A et al. Preliminary NINDS neuropathologic criteria for Steele‐Richardson‐Olszewski syndrome (PSP). Neurology 1994; 44: 2015–2019.
   PubMed Web of Science ®Google Scholar
• Feany MB, Mattiace LA, Dickson DW. Neuropathological overlap of progressive supranuclear palsy, Pick's disease and corticobasal degeneration. J Neuropath Exp Neurol 1996; 55: 53–67.
   PubMed Web of Science ®Google Scholar
• Constantinescu R, Richard I, Kurlan R. Levodopa responsiveness in disorders with parkinsonism: A review of the literature. Move Disord 2007; 15: 2141–2148.
   Google Scholar
• Rascol O, Sieradzan K, Peyro‐saint‐paul H, Thalamus C, Brefel‐courbon C, Senard JM, Ladure P et al. Efaroxan, an alpha‐2‐antagonist, in the treatment of progressive supranuclear palsy. Move Disord 1998; 13: 673–676.
   PubMed Web of Science ®Google Scholar
• Guttman M. Double‐blind, placebo‐controlled trial of pramipexole in progressive supranuclear palsy (PSPP). Neurology 2001; 56 (Suppl3): A458‐A459.
   Google Scholar
• Mayr BJ, Bonelli RN, Niederwiesser G, Koltringer P, Reiscker F. Zolpidem in progressive supranuclear palsy. Eur J Neurol 2002; 9: 184–185.
   PubMed Web of Science ®Google Scholar
• Frattali CM, Sonies BC, Chi‐fishman G, Litvan I. Effects of physostigmine on swallowing and oral motor function in patients with progressive supranuclear palsy: a pilot study. Dysphagia 1999; 14: 165–168.
   PubMed Web of Science ®Google Scholar
• Litvan I, Phipps M, Pharr VL, Hallett M, Grafman J, Salazar A. Randomised placebo‐controlled trial of donepezil in patients with progressive supranuclear palsy. Neurology 2001; 57: 467–473.
   PubMed Web of Science ®Google Scholar
• Poujois A, Vidailhet M, Trocello JM, Bourdain F, Gaymard B, Rivand‐pechoux S. Effect of gabapentin on oculomotor control and parkinsonism in patients with progressive supranuclear palsy. Eur J Neurol 2007; 14: 1060–1062.
   Web of Science ®Google Scholar
• Bashir K, Elbe RJ, Ghabrial M, Struble RG. Hemianopsia in dementia with Lewy bodies. Arch Neurol 1998; 55: 1132–1135.
   PubMedGoogle Scholar
• Grandas F, Esteban A. Eyelid motor abnormalities in progressive supranuclear palsy. J Neurol Transm (Supp) 1994; 42: 33–41.
   Google Scholar
• Valls‐sole J, Valldeoriola F, Tolosa E, Marti MJ. Distinctive abnormalities of facial reflexes in patients with progressive supranuclear palsy. Brain 1997; 120: 1877–1883.
   Web of Science ®Google Scholar
• Gironell A, Kulisevsky J, Roig C, Pascual‐sedano B, Rodriquez‐fornells A, Otermin P. Diagnostic potential of acoustic startle reflex, acoustic blink reflex and electrooculography in progressive supranuclear palsy: a prospective study. Move Disord 2003; 18: 1273–1279.
   PubMed Web of Science ®Google Scholar
• Piccione F, Mancini E, Tonin P, Bizzarini M. Botulinum toxin treatment of apraxia of eyelid opening in progressive supranuclear palsy: report of two cases. Arch Phys Med Rehab 1997; 78: 525–529.
   PubMed Web of Science ®Google Scholar
• Lamberti P, De mari M, Zenzola A, Aniello MS, Defazio G. Frequency of apraxia of eyelid opening in the general population and in patients with extrapyramidal disorders. Neurol Sci 2002; 23: Supp2S81‐S82.
   Google Scholar
• Defazio G, De mari M, De salvia R, Lamberti P, Giorelli M, Livrea P. Apraxia of eyelid opening induced by levodopa therapy and apomorphine in atypical parkinsonism (possible progressive supranuclear palsy): a case report. Clin Neuropharmacol 1999; 22: 292–294.
   Web of Science ®Google Scholar
• Carrilho PEM, Barbosa ER. Progressive supranuclear palsy in a sample of Brazilian population: Clinical features of 16 patients. Arq de Neuro-Psiqinatr 2002; 60: 917–922.
   Web of Science ®Google Scholar
• Litvan I, Fitzgibbon EJ. Can tropicamide eye drop response differentiate patients with progressive supranuclear palsy and Alzheimer's disease from healthy control subjects? Neurology 1996; 47: 1324–1326.
   Web of Science ®Google Scholar
• Shinotoh H, Namba H, Yamaguchi M, Kukushi K, Nagatsuka S, Iyo M, Asahina M et al. Positron emission tomographic measurement of acetylcholinesterase activity reveals differential loss of ascending cholinergic systems in Parkinson's disease and progressive supranuclear palsy. Anns Neurol 1999; 46: 62–69.
   PubMed Web of Science ®Google Scholar
• Scinto LFM, Daffner KR, Dressler D, Ransil BI, Rentz D, Weintraub S, Mesulam M et al. Potential non‐invasive neurobiological test for Alzheimer's disease. Science, 1994; 266: 1051–1054.
   Web of Science ®Google Scholar
• Caputo L, Casartelli M, Perrone C, Santori M, Annoni G, Vergani C. The ‘eye‐test’ in recognition of late‐onset Alzheimer's disease. Arch Geront Ger 1998; 27: 171–177.
   Web of Science ®Google Scholar
• Granholm E, Morris S, Galasko D, Shults C, Rogers E, Vukov B. Tropicamide effects on pupil size and papillary light reflexes in Alzheimer's and Parkinson's disease. Int J Psychophysiol 2003; 47: 95–115.
   PubMed Web of Science ®Google Scholar
• Schmidt C, Herling B, Prieur S, Junghanns S, Schweitzer K, Globas C, Schols L et al. Pupil diameter in darkness differentiates progressive supranuclear palsy (PSP) from other extrapyramidal syndromes. Move Disord 2007: 22: 2123–2126.
   PubMed Web of Science ®Google Scholar
• Rascol O, Sabatini U, Simonett‐amoreau M, Montrastruc JL, Rascol A, Clanet M. Square‐wave jerks in parkinsonism syndromes. J Neurol Neurosurg Psychiatr 1991; 54: 599–602.
   PubMed Web of Science ®Google Scholar
• Friedman DI, Jankovic J, Mccrary JA. Neuro‐ophthalmic findings in progressive supranuclear palsy. J Clin Neuroophthalmol 1992; 12: 104–109.
   PubMedGoogle Scholar
• Koop G, Grarf M. Steele‐Richardson‐Olszewski syndrome: A report on two cases. Klin Monats Augenheil 2007; 224: 799–803.
   Web of Science ®Google Scholar
• Pinkhardt EH, Jurgens R, Becker W, Valdarno F, Ludolph AC, Kassubek J. Differential diagnostic value of eye movement recording in PSP‐parkinsonism, Richardson's syndrome and idiopathic Parkinson's disease. J Neurol 2008; 155: 1916–1925.
   Google Scholar
• Kim C, Lee HW, Park MY. Exodeviated ophthalmoplegia in a patient with progressive supranuclear palsy. J Kor Med Sci 2009; 24: 982–984.
   Web of Science ®Google Scholar
• Revaud‐pechoux S, Vidailhet M, Gallouedec G, Litvan I, Gaymard B, Pierrot‐deseilligny C. Longitudinal ocular motor study in corticobasal degeneration and progressive supranuclear palsy. Neurology 2000; 54: 1029–1032.
   Web of Science ®Google Scholar
• Bhidayasiri R, Riley DE, Somers JT, Lerner AJ, Buttner‐ennever JA, Leigh RJ. Pathophysiology of slow vertical saccades in progressive supranuclear palsy. Neurology 2001; 57: 2070–2077.
   PubMed Web of Science ®Google Scholar
• Rottach KG, Riley DE, Discenna AO, Zivotofsky AZ, Leigh RJ. Dynamic properties of horizontal and vertical eye movements in parkinsonian syndromes. Ann Neurol 1996; 39: 368–377.
   PubMed Web of Science ®Google Scholar
• Halliday GM, Hardman CD, Cordato NJ, Hely MA, Morris JGL. A role for the substantia nigra pars reticulata in the gaze palsy of progressive supranuclear palsy. Brain 2000; 123: 724–732.
   PubMed Web of Science ®Google Scholar
• Sereno AB, Briand KA, Amador SC, Szapiel SV. Disruption of reflexive attention and eye movements in an individual with a collicular lesion. J Clin Exp Neuropsych 2006; 28: 145–166.
   PubMed Web of Science ®Google Scholar
• Das VE, Leigh RJ. Visual‐vestibular interaction in progressive supranuclear palsy. Vision Res 2000; 40: 2077–2081.
   Web of Science ®Google Scholar
• Malessa S, Gaymard B, Rivaud S, Cervera P, Hirsch H, Verny M, Duyckaerts C et al. Role of pontine nuclei damage in smooth‐pursuit impairment of progressive supranuclear palsy: a clinico‐pathological study. Neurology 1994; 44: 716–721.
   Web of Science ®Google Scholar
• Matsumoto H, Ohminami S, Goto J, Tsuji S. Progressive supranuclear palsy with wall‐eyed bilateral internuclear ophthalmoplegia syndrome. Arch Neurol 2008; 65: 827–829.
   Google Scholar
• Garbutt S, Riley DE, Kumar AN, Han Y, Harwood MR, Leigh RJ. Abnormalities of optokinetic nystagmus in progressive supranuclear palsy. J Neurol Neurosurg Psychiatr 2004; 75: 1386–1394.
   PubMed Web of Science ®Google Scholar
• Rascol O, Sabatini U, Fabre N, Senard JM, Simonett‐amoreau M, Montastruc JL, Clanet M et al. Abnormal vestibulo‐ocular cancellation in multiple system atrophy and progressive supranuclear palsy but not in Parkinson's disease. Move Disord 1995; 10: 163–170.
   Web of Science ®Google Scholar
• Langheinrich T, Van elst LT, Lagreze WA, Bach M, Lucking CH, Greenlee MW. Visual contrast response functions in Parkinson's disease: evidence from electroretinogram, visually evoked potentials and psychophysics. Clin Neurophysiol 2000; 111: 66–74.
   PubMed Web of Science ®Google Scholar
• Masanaka T, Hisao T, Keita K, Yasunobu K, Hiroo Y, Bungo O. Multi‐modal evoked potentials in corticobasal degeneration, progressive supranuclear palsy, and Alzheimer's disease. In: Unveiling the Mystery of the Brain: Neurophysiological Investigation of Brain Function. Int Cong Ser 2005; 1278: 145–148.
   Google Scholar
• Pierrot‐deseilligny C, Turell E, Penet C, Lebrigand D, Pillon B, Chain F, Agid Y. Increased wave P300 latency in progressive supranuclear palsy. J Neurol Neurosurg Psychiatr 1989; 52: 656–658.
   Web of Science ®Google Scholar
• Johnson R, Litvan I, Grafman J. Progressive supranuclear palsy: altered sensory processing leads to degraded cognition. Neurology 1991; 41: 1257–1262.
   PubMed Web of Science ®Google Scholar
• Koga Y, Nagata K, Hirata K. Hypothesis on the P300 generators based on visual P300 results in neurological disorders. Brain Topogography Today: Int Cong Series 1997; 1147: 354–357.
   Google Scholar
• Wang LH, Kuroiwa Y, Kamitani T, Li M, Takahashi T, Suzuki Y, Shimamura M et al. Visual event‐related potentials in progressive supranuclear palsy, corticobasal degeneration, striatonigral degeneration and Parkinsons's disease. J Neurol 2000; 247: 356–363.
   Web of Science ®Google Scholar
• Podoll K, Schwarz M, Noth J. Language problems in progressive supranuclear palsy. Brain 1991; 114: 1457–1472.
   PubMed Web of Science ®Google Scholar
• Sachin S, Shukla G, Goyal V, Singh S, Aggrawal V, Guresh‐kumar, Behari M. Clinical speech impairment in Parkinson's disease, progressive supranuclear palsy and multiple system atrophy. Neurology India 2008; 56: 122–126.
   Web of Science ®Google Scholar
• Diederich NJ, Goetz CG, Stebbins GT. Repeated visual hallucinations in Parkinsons's disease as disturbed external/internal perceptions: Focussed review and a new integrative model. Move Disord 2005; 20: 130–140.
   PubMed Web of Science ®Google Scholar
• Ebersbach G. Hallucinations and psychosis in Parkinson's disease: consequences for diagnosis and management. Nervenheil 2008; 27: 709.
   Google Scholar
• Williams DR, Warren JD, Lees AJ. Using the presence of visual hallucinations to differentiate Parkinson's disease from atypical parkinsonism. J Neurol Neurosurg Psychiatr 2008; 79: 652–655.
   PubMed Web of Science ®Google Scholar
• Cooper AD, Josephs KA. Photophobia, visual hallucinations, and REM sleep behaviour disorder in progressive supranuclear palsy and corticobasal degeneration: A prospective study. Parkinson Rel Disord 2009; 15: 59–61.
   PubMed Web of Science ®Google Scholar
• Averbuch‐heller L, Paulson GW, Daroff RB, Leigh RJ. Whipple's disease mimicking progressive supranuclear palsy, the diagnostic value of eye movement recording. J Neurol Neurosurg Psychiatr 1999; 66: 532–535.
   PubMed Web of Science ®Google Scholar
• Antoniades CA, Bak TH, Carpenter RHS, Hodges JR, Barker RA. Diagnostic potential of saccadometry in progressive supranuclear palsy. Biomarkers in Medicine 2007; 1: 487–490.
   Web of Science ®Google Scholar
• Altiparmak UE, Eggenberger E, Coleman A, Condon K. The ratio of square wave jerk rates to blink rate distinguishes progressive supranuclear palsy from Parkinson's disease. J Neuroophthalmol 2006; 26: 257–259.
   PubMed Web of Science ®Google Scholar
• Anderson T, Luxon L, Quinn N, Daniel S, Marsden CD, Bronstein A. Oculomotor functions in multiple system atrophy: clinical and laboratory features in 30 patients. Move Disord 2008; 23: 977–984.
   PubMed Web of Science ®Google Scholar
• Brett FM, Henson C, Staunton H. Familial diffuse Lewy body disease, eye movement abnormalities and distribution of the pathology. Arch Neurol 2002; 59: 464–467.
   Google Scholar
• Koch JM, Datta G, Makdoom S, Grossberg GT. Unmet visual needs of Alzheimer's disease patients in long‐term care facilities. J Am Med Dir Assoc 2005; 6: 233–237.
   PubMedGoogle Scholar
• Sadowski B. An optical device for patients with downgaze problems shown by a patient suffering from Steele‐Richardson‐Olszewski syndrome. Neuro-Ophthalmol 2000; 24: 311–314.
   Web of Science ®Google Scholar
• Di fabio RP, Zampieri C, Tuite P. Gaze control and foot kinematics during stair climbing: Characteristics leading to fall risk in progressive supranuclear palsy. Phys Ther 2008; 88: 240–250.
   Web of Science ®Google Scholar
• Zampieri C, Di fabio RP. Improvement of gaze control after balance and eye movement training in patients with progressive supranuclear palsy: A quasi‐randomised controlled trial. Arch Phys Med Rehab 2009; 90: 263–270.
   Web of Science ®Google Scholar